Current management of castrate-resistant prostate cancer

Prostate cancer (PCa) is the most frequently diagnosed cancer in North America. Castrate-resistant pca presents a spectrum of disease ranging from rising PSA levels in the absence of metastases or symptoms and despite androgen-deprivation therapy, to metastases and significant debilitation from cancer symptoms. Castrate-resistant PCa is usually suspected in patients with new symptoms on androgen deprivation therapy, with a rising PSa, or with …